Therefore, the primary objective of this study was to validate and assess feasibility of the anti-tumor properties of these MNS1 compounds in a series of patient-derived HGGs to provide the platform for further therapeutic advances in the management of these dismal diseases. The gene discussed is MNS1; the disease is neoplasm.